6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02982512
(ClinicalTrials.gov)
May 1, 201728/11/2016Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's DiseaseEffects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's DiseaseDexmedetomidine;Deep Brain Stimulation;Parkinson DiseaseDrug: DexmedetomidineClinica Universidad de Navarra, Universidad de NavarraNULLUnknown status18 YearsN/AAll12Phase 4Spain
2ChiCTR-IOR-16010168
2016-12-202016-12-15Propofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantationPropofol-remifetanyl vs dexmedetomidine continous infusion for deep brain stimulation implantation Parkinson's Diseasepropofol-remifentanyl group:propofol-remifentany infusion for monitored anesthesia care during awake deep brain stimulation surgery;dexmedetomidine group:dexmedetomidine infusion for monitored anesthesia care during awake deep brain stimulation surgery;West China Hospital, Sichuan UniversityNULLRecruiting18Bothpropofol-remifentanyl group:25;dexmedetomidine group:25;China
3ChiCTR2000037957
2016-12-012020-09-07Clinical study of dexmedetomidine on deep brain stimulation in middle-aged and elderly patients with Parkinson's diseaseClinical study of dexmedetomidine on deep brain stimulation in middle-aged and elderly patients with Parkinson's disease Deep brain stimulation in patients with Parkinson's diseaseExperimental group:conscious sedation with dexmedetomidine;control group:Pump in normal saline;Shanghai Jing'an District Central HospitalNULLCompleted4575BothExperimental group:27;control group:9;China
4EUCTR2016-002680-34-ES
(EUCTR)
20/10/201605/08/2016Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease.Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease. Parkinson's disease
MedDRA version: 19.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
Trade Name: Dexdor
Product Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Other descriptive name: DEXMEDETOMIDINA
Clínica Universidad de Navarra/Universidad de NavarraNULLNot RecruitingFemale: yes
Male: yes
12Phase 4Spain
5NCT02256319
(ClinicalTrials.gov)
September 201430/9/2014Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted StimulatorsEffects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted StimulatorsParkinson's DiseaseDrug: Dexmedetomidine;Drug: PropofolClinica Universidad de Navarra, Universidad de NavarraNULLCompleted18 YearsN/ABoth12Phase 4Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2014-000868-17-ES
(EUCTR)
26/06/201417/03/2014Effect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulatorsEffect of dexmedetomidine vs propofol on basal ganglia activity (local field potentials) recorded through implanted stimulators Parkinson's disease
MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
Trade Name: Dexdor
Product Name: Dexdor
INN or Proposed INN: DEXMEDETOMIDINE
Other descriptive name: DEXMEDETOMIDINA
Trade Name: Propofol-Lipuro
Product Name: Propofol-Lipuro
INN or Proposed INN: PROPOFOL
Other descriptive name: PROPOFOL
Clínica Universidad de Navarra/Universidad de NavarraNULLNot RecruitingFemale: yes
Male: yes
Spain
7NCT01789385
(ClinicalTrials.gov)
February 20132/2/2013Anesthesia for Deep Brain StimulationAnesthesia for Deep Brain Stimulation for the Treatment of Parkinsons DiseaseParkinsons DiseaseDrug: DexmedetomidineDiskapi Teaching and Research HospitalNULLCompleted19 Years85 YearsBoth26Phase 4Turkey
8NCT01721460
(ClinicalTrials.gov)
November 201230/10/2012Effects of Dexmedetomidine on Activity in the Subthalamic NucleusEffects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation SurgeryParkinson's Disease;Deep Brain Stimulation SurgeryDrug: DexmedetomidineUniversity of Wisconsin, MadisonNULLCompleted18 Years85 YearsAll6Phase 4United States
9NCT00608231
(ClinicalTrials.gov)
January 20087/1/2008Dexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationDexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationParkinson's Disease;Essential Tremor;DystoniaDrug: Dexmedetomidine Hydrochloride Infusion;Drug: Normal SalineVanderbilt UniversityNULLWithdrawn18 YearsN/ABoth0Phase 2;Phase 3United States